Alpha Tau Medical Ltd. (DRTS) Form 6-K — Jun 11, 2026
Alpha Tau Medical (DRTS) received FDA clearance to resume patient enrollment in its REGAIN trial for recurrent glioblastoma, following a review of interim safety data from the first three patients. The FDA authorized the company to treat the remaining seven patients in the study and added two new U.S. academic cancer centers as clinical sites. Interim results from the initial three patients showed 100% local disease control and a 67% complete response rate, with only one manageable grade 3 serious adverse event.
Key figures
- Grade 3 sae count
- 1
- New us sites added
- 2
- Total trial capacity
- 10
- Complete response rate
- 67%
- Annual us gbm diagnoses
- 14000
- Interim patients treated
- 3
- Local disease control rate
- 100%
- Remaining patients to enroll
- 7
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.